MINNEAPOLIS, MN, US, Dec. 11, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, achieved a significant milestone – the sale of its signature product Spryng with OsteoCushion Technology to more than 600 veterinary clinics in 49 states.
"We are incredibly excited about the acceptance by veterinarians of our life changing product, Spryng with OsteoCushion Technology, which has been distributed to more than 600 clinics in 49 states," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The rapid increase in the number of clinics purchasing Spryng demonstrates an advancement in awareness of Spryng throughout the veterinary community. This advance was demonstrated by the increase of veterinarian inquiries and podium speaker references related to Spryng at the American Association of Equine Practitioners ("AAEP") conference over the past three years. When we first launched Spryng at the AAEP conference in Nashville three years ago no one knew about the product; last year in San Antonio veterinarians were informing us that they had heard of Spryng, but were unaware of veterinarians using the product; a few weeks ago at the AAEP conference in San Diego veterinarians were sharing with us that they knew veterinarians using the product and experiencing beneficial results. Such awareness gives us confidence that veterinarians are reaching for Spryng as a viable option for the management of lameness and joint related afflictions, such as osteoarthritis."
SPRYNG with OsteoCushionTechnology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of lameness and other joint-related afflictions, such as osteoarthritis.
"We are also seeing enthusiasm surrounding Spryng in the veterinary community with veterinarians sending us videos and images touting the benefits of Spryng," said Mr. Lai. "For example, Dr. Tomas Infernuso recently provided a video demonstrating the injection of Spryng in the contralateral knee of a dog following a TPLO procedure."
To view an injection of Spryng performed by Dr. Infernuso please visit:
.
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit and rynghealth.com/.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
美國明尼蘇達州明尼阿波利斯,2023年12月11日(GLOBE NEWSWIRE)——專注於伴侶動物創新醫療設備和療法商業化的新興生物醫學設備公司PetVivo Holdings, Inc.(納斯達克:PETV & PETVW)(以下簡稱 “公司”)實現了一個重要的里程碑——其標誌性產品Spryng的銷售 搭配 OseoC 爲49個州的600多家獸醫診所提供技術。
PetVivo Holdings, Inc.首席執行官約翰·賴說:“獸醫接受我們的改變生活的產品Spryng with OsteoCushion技術,我們感到非常興奮,該產品已分銷到49個州的600多家診所。購買Spryng的診所數量的迅速增加表明整個獸醫界對Spryng的認識有所提高。在過去三年中,在美國馬術從業者協會(“AAEP”)會議上,與Spryng相關的獸醫諮詢和講臺演講者推薦次數的增加就證明了這一進步。三年前,當我們在納什維爾的AAEP會議上首次推出Spryng時,沒有人知道該產品;去年在聖安東尼奧,獸醫告訴我們,他們聽說過Spryng,但不知道獸醫在使用該產品;幾周前,在聖地亞哥的AAEP會議上,獸醫與我們分享說,他們知道獸醫正在使用該產品並取得了有益的結果。這種認識使我們有信心,獸醫會選擇Spryng作爲管理跛行和關節相關疾病(例如骨關節炎)的可行選擇。”
噴湧而出 搭配 OseoC技術,是一種關節內注射獸用醫療器械,由消毒的細胞外基質微粒組成。已發現 Spryng 的微粒會吸附在動物的關節滑膜上,然後與動物的滑膜下組織融合。這種動作促進了適當的關節機制的恢復,從而有助於控制跛行和其他與關節相關的疾病,例如骨關節炎。
賴先生說:“我們還看到了獸醫界對Spryng的熱情,獸醫向我們發送了視頻和圖片,吹捧Spryng的好處。”“例如,托馬斯·因費爾努索博士最近提供了一段視頻,演示了在TPLO手術後將Spryng注射到狗的對側膝蓋中。”
要查看 Infernuso 博士進行的 Spryng 注射,請訪問:
。
有關 PetVivo Holdings, Inc. 及其創新產品 Spryng 的更多信息,請聯繫 info1@petvivo.com 或者訪問 和 rynghealth.com/。
關於 PetVivo 控股有限公司
PetVivo Holdings Inc.(納斯達克股票代碼:PETV & PETVW)是一家新興的生物醫學設備公司,目前專注於用於伴侶動物的創新醫療設備和療法的製造、商業化和許可。該公司的戰略是利用人類療法以節省資金和時間的方式治療伴侶動物。該戰略的一個關鍵組成部分是加快獸醫醫療器械的收入時間表,獸醫醫療器械比監管更爲嚴格的藥品和生物製劑更早進入市場。
PetVivo 擁有十七種用於治療動物和人的產品。二十項專利組合保護公司的生物材料、產品、生產工藝和使用方法。該公司的主要產品SPRYNG是獸醫給藥的關節內注射劑,用於治療狗和馬的跛行和其他關節相關疾病,包括骨關節炎,目前已向獸醫進行商業銷售。
聯繫人:
首席執行官賴國強
PetVivo 控股有限公司
電子郵件: info1@petvivo.com
(952) 405-6216
前瞻性商業陳述:
上述材料可能包含經修訂的1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的 “前瞻性陳述”。前瞻性陳述包括所有不僅與歷史或當前事實相關的陳述,包括但不限於公司的擬議開發和商業時間表,並且可以通過使用諸如 “可能”、“將”、“期望”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛力”、“應該”、“繼續” 等詞語或其他類似詞語的負面版本來識別。前瞻性陳述不能保證未來的行爲或表現。這些前瞻性陳述基於公司當前可用的信息及其當前的計劃或預期,並存在許多可能對當前計劃產生重大影響的不確定性和風險。公司截至2023年3月31日止年度的10-K表年度報告以及向美國證券交易委員會提交的其他定期和當前報告中詳細描述了與公司業務有關的風險。無論是由於新信息、未來事件還是其他原因,公司沒有義務更新或更改其前瞻性陳述,也明確表示不承擔任何此類義務。